Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Most patients with seronegative villous atrophy do not have celiac disease

The latest issue of Gut reports on the clinical and phenotypical assessment of seronegative villous atrophy in a large adult cohort studied over a 15-year period.

News image

Seronegative villous atrophy is commonly attributed to celiac disease.

However, there are other causes of seronegative villous atrophy.

More recently angiotensin-2-receptor-blockers have been reported as an association but data on seronegative villous atrophy have been limited to centers evaluating complex case referrals, and not seronegative villous atrophy in general.

Dr David Sanders and colleagues from the United Kingdom provide clinical outcomes and associations in a large prospective study overseeing all newcomers with seronegative villous atrophy.

Over a 15-year period, the team evaluated 200 adult patients with seronegative villous atrophy at a UK center.

Of the 200 seronegative villous atrophy cases, seronegative-non-celiac disease represented 69%
Gut

A diagnosis of either seronegative celiac disease or seronegative non-celiac disease was reached.

The researchers made baseline comparisons between the groups, with 343 seropositive celiac disease subjects serving as controls.

Of the 200 seronegative villous atrophy cases, seronegative celiac disease represented 31% and seronegative-non-celiac disease 69%.

The researchers observed that human leucocyte antigen (HLA)-DQ2 and/or DQ8 genotype was present in 61%, with a 51% positive predictive value for seronegative-non-celiac disease.

The breakdown of identifiable causes in the seronegative-non-celiac disease group comprized infections, inflammatory/immune-mediated disorders, and drugs.

However, the research team found no cause in 18%, and of these, 72% spontaneously normalized duodenal histology while consuming a gluten-enriched diet.

The researchers observed that an independent factor associated with seronegative-non-celiac disease was non-white ethnicity.

The team noted that 66% of non-whites had GI infections.

On immunohistochemistry all groups stained positive for CD8-T-cytotoxic intraepithelial lymphocytes.

However, additional CD4-T helper intraepithelial lymphocytes were occasionally seen in seronegative-non-celiac disease mimicking the changes associated with refractory celiac disease.

Dr Sanders' team concluded, "Most patients with seronegative villous atrophy do not have celiac disease, in particular those who are not white."

"Furthermore, a subgroup with no obvious etiology will show spontaneous histological resolution while consuming gluten."

"These findings suggest caution in empirically prescribing a gluten-free diet without investigation."

Gut 2017;66:1563-1572
16 August 2017

Go to top of page Email this page Email this page to a colleague

 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 20 February 2018 
Complications and surveillance colonoscopies
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us